These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32941237)

  • 1. Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer.
    Xu JL; Wang XZ; Jiang HN; Chen Y; Wang R; Shu YQ
    Chin Med J (Engl); 2020 Oct; 133(20):2495-2497. PubMed ID: 32941237
    [No Abstract]   [Full Text] [Related]  

  • 2. MEK inhibitors under development for treatment of non-small-cell lung cancer.
    Kim C; Giaccone G
    Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK/MAPK inhibitors.
    Dy G
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S474-5. PubMed ID: 21102245
    [No Abstract]   [Full Text] [Related]  

  • 4. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.
    Papadimitrakopoulou V; Adjei AA
    J Thorac Oncol; 2006 Sep; 1(7):749-51. PubMed ID: 17409953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.
    Jeanson A; Boyer A; Greillier L; Tomasini P; Barlesi F
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):11-17. PubMed ID: 30513023
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.
    Kubo T; Watanabe H; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Rai K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2020 Dec; 50(12):1447-1453. PubMed ID: 32869100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis.
    Zheng SY; Cui HJ; Duan H; Peng YM; Li Q; Sun CY; Zhang JY; Shen W; Zhang X; Tan K; Jiang X
    Clin Transl Oncol; 2020 Jul; 22(7):1146-1154. PubMed ID: 31748961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer.
    Shannon VR
    Curr Opin Pulm Med; 2020 Jul; 26(4):326-340. PubMed ID: 32452900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.
    Lin JJ; Chin E; Yeap BY; Ferris LA; Kamesan V; Lennes IT; Sequist LV; Heist RS; Mino-Kenudson M; Gainor JF; Shaw AT
    J Thorac Oncol; 2019 Jan; 14(1):135-140. PubMed ID: 30205166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.
    Li Y; Yang Z; Li W; Xu S; Wang T; Wang T; Niu M; Zhang S; Jia L; Li S
    Oncotarget; 2016 Feb; 7(6):6748-64. PubMed ID: 26745678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced?
    Shaw AT
    Clin Adv Hematol Oncol; 2017 Dec; 15(12):941-945. PubMed ID: 29315286
    [No Abstract]   [Full Text] [Related]  

  • 15. Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma.
    Kohler J; Catalano M; Ambrogio C
    Curr Med Chem; 2018 Feb; 25(5):558-574. PubMed ID: 28554329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted kinase inhibitors in lung cancer: from EGFR to patients.
    Apolone G; La Vecchia C; Garattini S
    Eur J Cancer; 2006 Jan; 42(2):124-5. PubMed ID: 16324837
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
    Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
    Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
    Sehgal K; Varkaris A; Viray H; VanderLaan PA; Rangachari D; Costa DB
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerance of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung disease.
    Matsumoto K; Adachi Y; Enomoto T
    Respirology; 2020 Aug; 25(8):892. PubMed ID: 32072709
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations.
    Zullo L; Rossi G; Dellepiane C; Tagliamento M; Alama A; Coco S; Longo L; Pronzato P; Maria A; Genova C
    Immunotherapy; 2021 Apr; 13(6):509-525. PubMed ID: 33626932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.